China, EU Respondents Optimistic About Prospects of Future Cooperation: GT Survey

China and the EU have had established diplomatic relations for more than half a century. From the establishment of formal diplomatic relations to the development into a comprehensive strategic partnership, China-EU relations have become one of the most influential bilateral relationships in the world today. Apart from China, from October 16 to November 4, 2025, the Global Times Institute (GTI) conducted a questionnaire survey across 20 EU member states, including Denmark, Sweden, Spain, Belgium, and Germany, using 21 languages such as Spanish, French, German, and Chinese. More than 16,300 valid questionnaires were collected. The survey data shows that a majority of people in both China and EU are interested in each other's cultures, have...
Anglais

Actus Nutrition Achieves Certified B Corporation™ Status

Actus Nutrition today announced that it has achieved Certified B Corporation™ status, joining a global community of businesses that value social and environmental performance, accountability, and transparency. For more than 80 years, Actus Nutrition has upcycled dairy-based raw materials into high-value nutrition ingredients used by customers around the world. Earning B Corp certification reflects the company’s belief that business success should create value not...
Anglais

Xsolla Connect Returns to Brighton

Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and...
Anglais

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

SHELTON, CT /ACCESS Newswire/ July 13, 2026 /NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). The Company is now getting ready...
Anglais

FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx

FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated...
Anglais

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Niagen Bioscience, Inc.(NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the...
Anglais